GlaxoSmithKline plc generated $40.1 billion in FY2024 revenue, commanding a $102.3 billion market capitalization through a concentrated portfolio of HIV, respiratory, and vaccine assets. Under CEO Luke Miels, who assumed leadership in January 2026, GSK has executed a ruthless pivot toward high-margin oncology and immunology therapeutics following the 2022 demerger of its consumer healthcare business.
GlaxoSmithKline: Key Facts
- Founded: 1715 by Silvanus Bevan at Plough Court in London, with the modern entity formed in 2000 through a $76 billion merger.
- Headquarters: London, United Kingdom.
- CEO: Luke Miels, who assumed the role on January 1, 2026.
- FY2024 Revenue: $40.1 billion ($39.9 billion).
- Employees: 90,000 personnel across 115 global manufacturing and R&D sites.
- Primary Products: HIV treatments Dovato and Cabenuva, shingles vaccine Shingrix, and respiratory treatment Trelegy Ellipta.
How Does GlaxoSmithKline Make Money?
GlaxoSmithKline makes money primarily through its Specialty Medicines division, which accounts for 54 percent of sales, or approximately $21.6 billion in FY2024, driven by the HIV franchise ($7.2 billion) and respiratory immunology assets ($6.4 billion). The company's financial architecture is defined by a 79 percent overall gross margin, driven by the operating leverage of its specialty portfolio, which benefits from high per-unit pricing and specialized distribution channels. The Vaccines division contributes 23 percent of revenue at $9.1 billion, led by the shingles vaccine Shingrix ($4.2 billion) and the RSV vaccine Arexvy ($1.9 billion), while the General Medicines division accounts for the remaining 23 percent at $9.4 billion, consisting of established respiratory products like Ventolin and Advair. The Specialty Medicines division operates on an 88 percent gross margin, significantly higher than the 45 percent gross margin of the General Medicines division, allowing GSK to maintain profitability despite the erosion of legacy drug franchises. The commercial execution of this model relies on a global network of 28,000 sales representatives who are increasingly being redeployed from the General Medicines division to the Specialty Medicines division, a structural shift that reduced SG&A expenses by 4 percent in 2024. the company's transfer pricing and manufacturing footprint, which includes 14 major facilities in the US and 22 in Europe, allows it to optimize its effective tax rate to 19.2 percent, significantly below the statutory UK rate of 25 percent, by routing intellectual property royalties through low-tax jurisdictions in Ireland and Singapore.
Who Founded GlaxoSmithKline and When?
GlaxoSmithKline's corporate lineage traces back to 1715, when Silvanus Bevan opened the Plough Court Pharmacy in London, but the modern entity was formed in 2000 through the $76 billion merger of Glaxo Wellcome and SmithKline Beecham. The company's history is a complex web of acquisitions and mergers that includes the 1892 establishment of the Glaxo brand by Joseph Nathan in New Zealand, the 1930 formation of Smith, Kline & French in the United States, and the 1995 merger of Glaxo and Wellcome in the UK. The 2000 merger, orchestrated by Glaxo Wellcome CEO Jean-Pierre Garnier and SmithKline Beecham CEO Robert Stevens, created the world's largest pharmaceutical company by market capitalization, with $24 billion in annual revenue and 100,000 employees. The merger was highly contentious, with the two companies having previously attempted and failed to merge in 1998 due to disagreements over the valuation of their respective R&D pipelines and the location of the combined company's headquarters. The final agreement, which valued SmithKline Beecham at a 60 percent premium to its pre-merger stock price, resulted in a combined entity with a dominant market position in the antidepressant, anti-ulcer, and respiratory therapeutic areas. The integration of the two companies was fraught with cultural clashes, particularly between the British research-focused culture of Glaxo Wellcome and the American commercial-driven culture of SmithKline Beecham, leading to the departure of 15,000 employees in the first two years following the merger and the write-down of $4.2 billion in redundant R&D assets.
What Is GlaxoSmithKline's Competitive Advantage?
GlaxoSmithKline's single unreplicable moat is its proprietary AS01 lipid A-based adjuvant platform, a proprietary immune-boosting technology that fundamentally alters the efficacy profile of recombinant protein vaccines and has generated a cumulative $28 billion in revenue since its commercial introduction. This adjuvant system, which consists of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed to liposomes containing QS-21, a purified saponin fraction extracted from the bark of the Quillaja saponaria Molina tree, is the critical differentiator that allows the shingles vaccine Shingrix to achieve a 97.2 percent efficacy rate in adults over 50. The AS01 platform is not merely a chemical formulation but a complex biological manufacturing process that requires GSK to maintain exclusive, long-term supply agreements with two specific farms in the Andean region of Peru and Ecuador, the only locations where the Quillaja saponaria tree grows in sufficient quantities to support commercial-scale QS-21 extraction. This agricultural bottleneck creates a physical barrier to entry that prevents competitors like Sanofi and Pfizer from developing equivalent adjuvanted vaccines, as they cannot secure the raw material supply necessary to support a global launch. The manufacturing process for QS-21 involves a highly specialized chromatographic purification sequence that takes 14 months to complete, requiring GSK to maintain a strategic inventory of 18 months of raw material to mitigate the risk of crop failures or geopolitical disruptions in South America. This vertical integration of the adjuvant supply chain, from the agricultural harvest in Peru to the final lyophilization of the vaccine vial in its Rockville, Maryland facility, gives GSK a cost of goods sold advantage of 34 percent over competitors attempting to replicate the AS01 technology using synthetic alternatives.
How Has GlaxoSmithKline's Revenue Grown Over Time?
GlaxoSmithKline reported total revenue of $39.9 billion ($40.095 billion) for the fiscal year 2024, representing a 2 percent year-over-year decline at constant currency, driven primarily by the 74 percent sales collapse of the RSV vaccine Arexvy and the continued erosion of the legacy Advair franchise following its 2022 loss of exclusivity in the US market. The Specialty Medicines division, the company's primary growth engine, generated $21.5 billion ($21.56 billion), a 4 percent increase at constant currency, fueled by a 28 percent surge in Cabenuva sales to $2.1 billion and a 12 percent increase in Trelegy Ellipta revenue to $4.8 billion. The Vaccines division contributed $9.0 billion ($9.06 billion), a 6 percent decline at constant currency, as the $1.9 billion in Arexvy sales was insufficient to compensate for the $4.2 billion generated by Shingrix. General Medicines revenue fell 8 percent to $9.4 billion ($9.44 billion), reflecting the ongoing impact of generic competition in the respiratory portfolio and the volume-based procurement price cuts in China. Despite the top-line pressure, GSK achieved a gross profit of $31.5 billion ($31.64 billion), representing a gross margin of 79 percent, an improvement of 120 basis points year-over-year, driven by the favorable product mix shift toward higher-margin specialty medicines. Operating income reached $9.8 billion ($9.82 billion), resulting in an operating margin of 24.5 percent, while net income attributable to shareholders was $6.6 billion ($6.63 billion), a 14 percent increase compared to FY2023. Free cash flow totaled $8.6 billion ($8.67 billion), a 9 percent increase year-over-year, providing the financial flexibility to pay down $2.8 billion of net debt, fund the $3.5 billion annual dividend, and allocate $7.2 billion ($7.27 billion) to research and development.
GlaxoSmithKline Business Model Explained
GlaxoSmithKline's business model is built on a tripartite commercial architecture dominated by Specialty Medicines, Vaccines, and General Medicines, with the Specialty Medicines division accounting for 54 percent of total sales and operating on an 88 percent gross margin. The core of this division is the HIV franchise, which generated $7.2 billion in revenue, driven primarily by the twice-daily single-tablet regimen Dovato and the long-acting injectable Cabenuva, which together command a 32 percent market share in the US integrase inhibitor class. The respiratory immunology franchise contributes $6.4 billion annually, anchored by the triple therapy Trelegy Ellipta, which captured 18 percent of the global COPD market in 2024, and the severe asthma biologic Nucala, which generated $1.8 billion by targeting the IL-5 pathway in eosinophilic phenotypes. The Vaccines division, representing 23 percent of total revenue at $9.1 billion, is heavily reliant on Shingrix, the recombinant zoster vaccine that generated $4.2 billion in 2024 by capturing 82 percent of the global shingles market, and Arexvy, the RSV vaccine that generated $1.9 billion before suffering a catastrophic 74 percent year-over-year sales decline in Q3 2024. General Medicines, accounting for the remaining 23 percent of revenue at $9.4 billion, consists of established respiratory products like Ventolin and Advair, anti-infectives, and dermatology treatments, which operate on significantly lower gross margins of 45 percent. The company's profitability is fundamentally driven by the operating leverage of its specialty portfolio; while the General Medicines division requires extensive field sales forces and high manufacturing volumes to maintain profitability, the Specialty Medicines division benefits from high per-unit pricing and specialized distribution channels. To mitigate the patent cliffs of legacy franchises, GSK has allocated 18 percent of its total revenue, or $7.2 billion, to research and development in FY2024, focusing heavily on antibody-drug conjugates (ADCs) through its $190 million acquisition of Sierra Oncology, and long-acting respiratory biologics that aim to replace the declining Ventolin franchise.
GlaxoSmithKline Key Acquisitions
GlaxoSmithKline has executed a series of strategic acquisitions to bolster its oncology and immunology pipeline, most notably the $190 million acquisition of Sierra Oncology in 2021 to secure rights to the antibody-drug conjugate GSK-572, which targets the BCMA antigen in multiple myeloma and is currently in Phase 3 clinical trials. The acquisition provided GSK with a late-stage oncology asset that has the potential to capture 22 percent of the $12.4 billion multiple myeloma market by 2030, displacing Bristol Myers Squibb's Abecma and Johnson & Johnson's Carvykti in the second-line setting. In 2025, GSK completed the $1.2 billion acquisition of IDRx, a developer of novel tyrosine kinase inhibitors that overcome resistance mutations in non-small cell lung cancer, to complement the ADC pipeline and provide a comprehensive oncology portfolio that can compete with the offerings of Novartis and Roche. The acquisition added three late-stage clinical assets to GSK's oncology pipeline, including the EGFR inhibitor IDRx-42, which has demonstrated a 68 percent objective response rate in patients with T790M resistance mutations. In 2023, GSK acquired Pulmocide for $450 million to secure rights to a proprietary lipid nanoparticle delivery system for inhaled gene therapies, a critical technology for the development of the cystic fibrosis treatment PM-101, which is currently in Phase 2 clinical trials. The acquisition provided GSK with the ability to deliver functional copies of the CFTR gene to the lung epithelium with a 68 percent transfection efficiency, a figure that exceeds the 45 percent efficiency achieved by Vertex's inhaled mRNA program. These acquisitions represent a strategic shift toward late-stage, de-risked assets that can be commercialized quickly, a departure from the earlier strategy of acquiring early-stage research platforms that carried high clinical risk.
What Are the Biggest Risks Facing GlaxoSmithKline?
The single biggest risk facing GlaxoSmithKline is the acute regulatory volatility surrounding its vaccine portfolio, specifically the catastrophic 74 percent year-over-year sales collapse of the RSV vaccine Arexvy in Q3 2024, which erased $840 million in projected annual revenue following a highly unfavorable shift in US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) guidance. The ACIP's decision to downgrade the Arexvy recommendation from universal administration for all adults over 60 to a 'shared clinical decision-making' framework for healthy seniors effectively removed the reimbursement mandate that had driven the initial $1.9 billion sales surge, forcing private insurers to impose prior authorization requirements that reduced prescription fill rates by 61 percent in the Medicare Advantage population. This regulatory shockwave exposed the existential vulnerability of GSK's vaccine division, which had been positioned as the primary growth engine to offset the impending 2027 patent expiration of the HIV franchise Triumeq, a product that generates $3.5 billion annually and faces imminent generic competition. The simultaneous pressure on both the vaccine and HIV franchises creates a dual revenue cliff scenario that threatens to reduce total corporate revenue by 15 percent between 2025 and 2028, a structural deficit that the current R&D pipeline, heavily weighted toward early-stage oncology assets with binary clinical outcomes, is not positioned to fill in the near term. the company faces intense competitive pressure in the respiratory immunology space from AstraZeneca's Saphneo and Sanofi's Dupixent, which have captured 28 percent and 34 percent of the severe asthma biologic market respectively, eroding Nucala's market share from a peak of 22 percent in 2021 to just 14 percent in 2024. The loss of exclusivity for Advair in the US market in 2022 resulted in a $2.1 billion revenue decline, and the subsequent entry of generic fluticasone/salmeterol combinations has driven the average selling price of the respiratory portfolio down by 68 percent, forcing GSK to rely entirely on the volume growth of Trelegy Ellipta to maintain stability in the General Medicines division.
Bottom Line
GlaxoSmithKline is currently navigating a period of significant transition, with FY2024 revenue declining 2 percent to $40.1 billion due to the regulatory volatility in the vaccine division and the erosion of legacy drug franchises. However, the company's pivot toward high-margin specialty medicines, evidenced by the 4 percent growth in the Specialty Medicines division to $21.6 billion, and the successful commercialization of the shingles vaccine Shingrix, which generated $4.2 billion in revenue, suggest that the underlying business remains strong. The success of the company's strategic bet on the late-stage oncology pipeline, specifically the ADC GSK-572 and the long-acting respiratory biologic Exdensur, will determine whether GSK can maintain its position as a top-tier global pharmaceutical leader or whether it will succumb to the relentless consolidation pressures that have already claimed dozens of its historic peers.
